Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and (18)F-FMISO PET

Tumoral hypoxia correlates with worse outcomes in glioblastoma (GBM). While bevacizumab is routinely used to treat recurrent GBM, it may exacerbate hypoxia. Evofosfamide is a hypoxia-targeting prodrug being tested for recurrent GBM. To characterize resistance to bevacizumab and identify those with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shiliang, Michalek, Joel E., Reardon, David A., Wen, Patrick Y., Floyd, John R., Fox, Peter T., Clarke, Geoffrey D., Jerabek, Paul A., Schmainda, Kathleen M., Muzi, Mark, Hyun, Hyewon, Lee, Eudocia Quant, Brenner, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027395/
https://www.ncbi.nlm.nih.gov/pubmed/33828310
http://dx.doi.org/10.1038/s41598-021-84331-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027395/
https://www.ncbi.nlm.nih.gov/pubmed/33828310
http://dx.doi.org/10.1038/s41598-021-84331-5

Ejemplares similares